Searchable abstracts of presentations at key conferences in endocrinology

ea0014p409 | (1) | ECE2007

Bone mineral density and bone markers in patients on long-term suppressive levothyroxine therapy for differentiated thyroid carcinoma

Mouton F. , D’Herbomez M. , Cao C. Do , Tison-Muchery F. , Marchandise X. , Wemeau J.-L.

Methods: In a prospective longitudinal study, 156 determinations of osteocalcine (OC) as a marker of bone formation, and of C-telopeptide of type-1 collagene (CTX and ICTP) as markers of bone resorption were performed in 103 patients {20 men (median age 50 years), 83 females (median age 56 years – 58% with age >50 years)} treated with suppressive levothyroxine therapy for DTC. Bone mineral density (BMD) of the hip was measured by dual X-ray absorpti...

ea0032p562 | Endocrine tumours and neoplasia | ECE2013

Are hibernoma or lipoma a marker of type 1 multiple endocrine neoplasia (MEN1) aggressiveness?

Kamoun M , Karrouz W , Le Mapihan K , d'Herbomez M , Beron A , Caiazzo R , Porchet N , Pattou F , Wemeau J L , Vantyghem M C

MEN1, autosomal dominant, is characterized by combined tumours of the parathyroid glands, pancreatic islet cells, and the anterior pituitary, sometimes associated with other endocrine (adrenocortical, foregut carcinoid) and nonendocrine (lipoma, angiofibroma, collagenoma, ependymoma, meningioma) tumors. It is caused by inactivating mutations of the MEN1 tumour suppressor gene (chromosome 11q13), encoding menin. Menin, involved in activation of gene transcription, regu...

ea0026p70 | Endocrine tumours and neoplasia | ECE2011

First prognostic analysis of stage III adrenocartical carcinoma patients after complete resection: a retrospective French Multicentric Study from the INCA-COMETE network

Do Cao C , Leboulleux S , Borget I , Bertherat J , De la Fouchardiere C , Hecart A C , Caron P , Tabarin A , Niccoli P , Rohmer V , Drui D , Schillo F , Raingeard I , Young J , Ghuzlan A , Borson-Chazot F , Bertagna X , Pattou F , Wemeau J L , Francis Z , Libe R , Aubert S , Baudin E

Objective: To assess outcome of stage III–ENSAT adrenocortical carcinoma (ACC) patients after complete macroscopic resection and prognostic factors for disease-free survival (DFS) and overall survival (OS).Methods: A retrospective review of 68 stage III ACC patients treated surgically between 1994 and 2009 in the French COMETE network was performed. Characteristics of patients were reviewed by a single investigator as well as the Weiss score by expe...